HISOAR(SZ:002099) 智通财经网·2025-12-29 08:19Core Viewpoint - The company Haishang Pharmaceutical (002099.SZ) has announced the initiation of the Phase II clinical trial for its innovative nucleic acid drug NWRD06, aimed at preventing postoperative recurrence of liver cancer, marking a significant advancement in cancer treatment [1][2]. Group 1 - Haishang Pharmaceutical's subsidiary, Beijing Guoxin Zhongshu Investment Management Co., has informed the company about the participation in the clinical trial of NWRD06, which has successfully enrolled its first subject [1]. - NWRD06 is the world's first therapeutic nucleic acid drug targeting the specific liver cancer marker GPC3, currently in Phase II clinical trials, showcasing an innovative mechanism that activates specific T-cell immunity to eliminate tumor cells [1]. - The potential applications of NWRD06 may extend beyond postoperative recurrence to early-stage cancer treatment and possibly even cirrhosis, indicating a biologically rational expansion of its indications [1]. Group 2 - The Phase I clinical study of NWRD06 has been completed at the Chinese Academy of Medical Sciences Cancer Hospital, emphasizing its core value in precisely identifying tumor cells and addressing micro-lesions that are inaccessible to surgical treatment [2]. - The successful launch of the Phase II clinical trial and the enrollment of the first subject represent a significant step towards clinical application, potentially offering a safe and non-invasive option for postoperative liver cancer patients to prevent recurrence and improve survival rates [2].